All Companies

Description	Status	Initial Date
Developing a software platform to support the emerging interventional oncology market.	Private	2005	View Profile
Developing a pipeline of innovative treatments for bladder diseases.	Private	2008	View Profile
Developing a new class of highly selective targeted and programmable therapeutics called Accurins™.	Private	2007	View Profile
Developing small molecule therapeutics for multiple oncology and immunology-based indications	Acquired	2001	View Profile
Developer of high-technology purification, analysis and synthesis products	Acquired	1991	View Profile
Design, development, manufacturing, and marketing of medical devices focused on women's health	Public	1989	View Profile
Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”.	Private	2004	View Profile
Delivers solutions for rich-media communication.	Private	1999	View Profile
Creating novel antibiotics for serious and life-threatening multi-drug resistant infections.	Public	2006	View Profile
Creating novel and differentiated biotherapeutics: first-of-a-kind protein-based drugs.	Private	2008	View Profile
Commercializing chemical catalysts for upgrading waste biomass to fuels, chemicals, and materials.	Private	2010	View Profile
Commercializing a family of low-cost, high-performance, sustainable polymers and other chemicals.	Private	2007	View Profile
Capitalizing on the global abundance of waste CO2 to economically produce renewable fuels and chemicals.	Private	2007	View Profile
Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs.	Private	2006	View Profile
Advancing the science and technology of corneal crosslinking.	Private	2009	View Profile
	Private	2008	View Profile
	Private	2000	View Profile
	Private	1998	View Profile

Flagship Ventures

All Companies